WÜRZBURG, Germany, December 17, 2025 /

德国维尔茨堡，2025年12月17日 /

Biotech

生物技术

Newswire

新闻专线

/ --

/ --

T-CURX GmbH

T-CURX 有限公司

(T-CURX) today announces the first closing of a $ 20M (€ 17.7M) Series A financing with a syndicate of European and Asian investors for accelerating clinical development of T-CURX non-viral clinical CAR-T therapies in AML and solid tumor indications, as well as advancing T-CURX proprietary non-viral technologies for .

(T-CURX) 今日宣布完成了一笔 2000 万美元（1770 万欧元）的 A 轮融资首次交割，投资方为一家欧洲和亚洲投资者组成的财团。这笔资金将用于加速 T-CURX 非病毒临床 CAR-T 疗法在急性髓系白血病（AML）和实体瘤适应症中的临床开发，并推进 T-CURX 的专有非病毒技术。

in vivo

体内

CAR-T generation.

CAR-T生成。

The Series A syndicate was led by BiomedVC and included Bayern Kapital, HighLight Capital (HLC), and i&iBio Fund, as additional investors along with existing and new individual investors.

A轮融资由BiomedVC领投，拜仁资本、高瓴资本（HLC）和i&iBio基金作为额外投资者参与，同时包括现有和新加入的个人投资者。

Ulf Grawunder, PhD, co-founder and CEO of T-CURX, commented on the closing of this Series A financing round for T-CURX:

乌尔夫·格拉温德博士，T-CURX的联合创始人兼首席执行官，就T-CURX完成此A轮融资发表了评论：

“I am very excited that T-CURX attracted such a high-profile, international investor’s syndicate, led by BiomedVC, for financing T-CURX`s non-clinical and clinical CAR-T technologies and CAR-T pipeline programs, respectively. It is a testament of the high quality of T-CURX data and the promise of our non-clinical and clinical non-viral CAR-T pipeline in AML & CLL and solid tumor indications going after novel targets.

“我感到非常兴奋，T-CURX吸引了由BiomedVC领投的高知名度国际投资者财团，为T-CURX的非临床和临床CAR-T技术以及CAR-T管线项目分别提供融资。这证明了T-CURX数据的高质量，以及我们在AML、CLL和实体瘤适应症中追求新靶点的非临床和临床非病毒CAR-T管线的潜力。”

It also highlights the high value of our unique approach to leverage non-viral CAR-vector and LNP technologies for highly economical and scalable in vivo CAR-T generation, in order to “democratize” CAR-T therapies for patients globally.”.

它还强调了我们独特的非病毒CAR载体和LNP技术在经济高效且可扩展的体内CAR-T生成中的高价值，目的是“普及”全球患者的CAR-T疗法。

Aristotelis Nastos, PhD, Managing Partner and investment director at lead-investor BiomedVC adds:

亚里士多德·纳斯塔斯博士，领先投资者BiomedVC的管理合伙人兼投资总监补充道：

“I am thrilled about leading a highly dedicated international syndicate of early-stage investors from Europe and Asia in this Series A financing for T-CURX. We were deeply impressed by the data on non-viral CAR-T product and technology development at T-CURX, the track-record and experience of T-CURX Founder’s and Management team and the promise of T-CURX non-viral CAR-T technolgies hold for making CAR-T therapies accessible and affordable for many cancer patients globally.

“我很高兴能够在这次T-CURX的A轮融资中，带领一支来自欧洲和亚洲的高度专注的国际早期投资者财团。T-CURX在非病毒CAR-T产品和技术开发方面的数据、T-CURX创始人及管理团队的过往记录与经验，以及T-CURX非病毒CAR-T技术为全球众多癌症患者提供可及且负担得起的CAR-T疗法的潜力，都给我们留下了深刻的印象。"

We are very much looking forward to support T-CURX to achieve all of their therapeutic and commercial ambitions”.

我们非常期待支持T-CURX实现其所有的治疗和商业目标。

T-CURX is a German Biotech company located in Würzburg and Munich, Germany,  spun-out of the laboratory of its co-founder, Prof. Michael Hudecek, University of Würzburg, who is a European KOL and pioneer in the development and clinical translation of non-viral CAR-T cell therapies to target various types of cancer..

T-CURX是一家德国生物技术公司，位于德国维尔茨堡和慕尼黑，由其联合创始人、维尔茨堡大学的迈克尔·胡德克教授（Michael Hudecek）创立，他是欧洲关键意见领袖（KOL）以及非病毒CAR-T细胞疗法开发和临床转化的先驱，致力于针对多种癌症类型。

Semantic keywords: Leukemia, Lymphocytic, Chronic, B-Cell; Receptors, Chimeric Antigen; Leukemia, Myeloid, Acute; AML; Chronic lymphocytic leukemia; CLL; T-CURX; Series A financing; BiomedVC; Bayern Kapital; HighLight Capital; i&iBio Fund; Chimeric Antigen Receptor T-cell therapy; CAR-T; non-viral CAR-T therapies; solid tumor indications; CAR-T pipeline; non-viral technologies; CAR-vector; LNP technologies; Ulf Grawunder; Aristotelis Nastos; CAR-T therapies; Würzburg; Michael Hudecek.

语义关键词：白血病、淋巴细胞、慢性、B细胞；嵌合抗原受体；白血病、髓性、急性；AML；慢性淋巴细胞白血病；CLL；T-CURX；A轮融资；BiomedVC；Bayern Kapital；高瓴资本；i&iBio基金；嵌合抗原受体T细胞疗法；CAR-T；非病毒CAR-T疗法；实体瘤适应症；CAR-T管线；非病毒技术；CAR载体；LNP技术；Ulf Grawunder；Aristotelis Nastos；CAR-T疗法；维尔茨堡；Michael Hudecek。

About

关于

T-CURX

T-CURX

T-CURX is a privately owned, German Biotech company based in Würzburg founded in 2017 with the vision of bringing next-generation CAR-T cell therapies manufactured with cost-effective and highly scalable non-viral CAR-T cell technologies to more cancer patients in need of more effective cancer therapies.

T-CURX是一家私人拥有的德国生物技术公司，位于维尔茨堡，成立于2017年，其愿景是通过使用具有成本效益且高度可扩展的非病毒CAR-T细胞技术，为更多需要更有效癌症治疗的患者提供下一代CAR-T细胞疗法。

T-CURX was spun out of the laboratory of T-CURX co-founder Prof. Michael Hudecek at the University of Würzburg and is led by Ulf Grawunder, PhD, a seasoned serial entrepreneur as CEO, who is also one of the co-founders. T-CURX leverages a portfolio of proprietary non-viral CAR-T technologies for scalable and cost-effective CAR-T manufacturing based on virus-free, Sleeping-beauty transposon gene transfer into patient’s T cells..

T-CURX 由 T-CURX 联合创始人迈克尔·胡德切克教授在维尔茨堡大学的实验室分离出来，现由资深连续创业者乌尔夫·格拉沃恩德博士（Ulf Grawunder）担任首席执行官领导公司，他也是联合创始人之一。T-CURX 利用一系列专有的非病毒 CAR-T 技术，基于无病毒的“睡美人”转座子基因转移技术，将基因导入患者的 T 细胞，从而实现可扩展且具有成本效益的 CAR-T 制造。

About BiomedVC

关于BiomedVC

BiomedVC is is a leading Swiss early-stage VC at the center of European biotech. BiomedVC builds companies around the most intriguing innovation. We strive to enable founders and their ideas. We work together on a basis of equality - as a team and with entrepreneurs. We focus on scientific excellence, building strong companies to create medical and commercial value and bring new medicines to market that improve patient’s lives..

BiomedVC是一家位于欧洲生物技术中心的瑞士领先早期风险投资公司。BiomedVC围绕最引人入胜的创新构建企业。我们致力于支持创始人及其创意。我们基于平等的原则共同合作——作为团队一员并与企业家携手。我们专注于科学卓越性，打造强大的公司以创造医学和商业价值，并将改善患者生活的新型药物推向市场。

Contact

联系

T-CURX

T-CURX

Ulf Grawunder, CEO

乌尔夫·格拉文德，首席执行官

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

For media enquiries

媒体查询请联络

+49-(0)-931-250-99-712

+49-(0)-931-250-99-712

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

Source: Biotech Newswire

来源：生物技术新闻